论文部分内容阅读
目的评价国产左西孟旦治疗慢性心力衰竭急性失代偿期患者的有效性及安全性。方法选取30例慢性心力衰竭患者在经常规治疗不能缓解症状时给予左西孟旦治疗。治疗前后检测患者的生命体征、离子、脑钠肽(BNP)、左室射血分数(LVEF)。结果治疗后BNP为(1985.45±1391.30)ng/L、LVEF为(36.01±6.03)%、血钾为(3.70±0.65)mmol/L,均优于治疗前的(2549.35±1668.30)ng/L、(29.80±5.05)%、(4.16±0.40)mmol/L,差异有统计学意义(P<0.05)。治疗后出现2例低血压、1例室性期前收缩、1例频发室性早搏,经减量或对症治疗后症状均得到缓解。结论国产左西孟旦能有效改善慢性心力衰竭患者的症状,增加心肌收缩力。
Objective To evaluate the efficacy and safety of domestic levosimendan in patients with acute decompensated chronic heart failure. Methods Thirty patients with chronic heart failure were treated with levosimendan when conventional treatment failed to relieve the symptoms. Before and after treatment, the patients’ vital signs, plasma BNP and left ventricular ejection fraction (LVEF) were measured. Results After treatment, the levels of BNP were (1985.45 ± 1391.30) ng / L, LVEF was (36.01 ± 6.03)%, and serum potassium was (3.70 ± 0.65) mmol / L, both of which were better than those before treatment (2549.35 ± 1668.30) ng / (29.80 ± 5.05)%, (4.16 ± 0.40) mmol / L respectively, the difference was statistically significant (P <0.05). After treatment, 2 cases of hypotension, 1 case of ventricular contraction, 1 case of frequent premature ventricular contractions, after reduction or symptomatic treatment were relieved symptoms. Conclusion Domestic levosimendan can effectively improve the symptoms of patients with chronic heart failure and increase myocardial contractility.